Leukemia, Myelomonocytic, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that besides morphology of megakaryocytes and other features, JAK2 V617F allelic burden can help differentiate CMML from PMF with monocytosis.
|
30447300 |
2019 |
Leukemia, Myelomonocytic, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous neoplasm in which JAK2 inhibition has demonstrated reductions in inflammatory cytokines and promising clinical activity.
|
30026572 |
2019 |
Leukemia, Myelomonocytic, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Notably, the frequency of JAK2 p.V617F mutation was higher in CMML-F patients compared with other CMML patients (P<0.001).
|
29596070 |
2018 |
Leukemia, Myelomonocytic, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological JAK2 inhibition may be an interesting approach to be systematically studied in patients with CMML.
|
27157043 |
2016 |
Leukemia, Myelomonocytic, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of note, 2 cases of JAK2 V617F+ primary myelofibrosis with SRSF2 mutation initially were diagnosed as CMML based on significant peripheral blood monocytosis.
|
25305095 |
2014 |
Leukemia, Myelomonocytic, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have performed genome-wide DNA methylation arrays and mutational analysis of TET2, IDH1, IDH2, EZH2 and JAK2 in a group of 24 patients with CMML.
|
22328940 |
2012 |
Leukemia, Myelomonocytic, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
JAK2 V617F mutation was detected after transformation to CMML in 1 of them; in the other, a novel translocation t(5;12)(p13;q24) was observed at the time of progression to acute leukemia.
|
21658659 |
2011 |
Leukemia, Myelomonocytic, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All bone marrow biopsies of JAK2(V617F)-mutated CMML showed increased erythropoiesis, a marked myeloid and megakaryocytic hyperplasia with occasionally clustered megakaryocytes, and a mild or moderate (grade 1 or 2) fibrosis; six cases showed an increased number of dilated sinusoids and reactive lymphoid nodules.
|
19734476 |
2009 |
Leukemia, Myelomonocytic, Chronic
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia.
|
17151700 |
2007 |
Leukemia, Myelomonocytic, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To study the prevalence of the Val617Phe JAK2 mutation in familial cases of myeloproliferative disorder (MPD) and its possible implication as a predisposing genetic factor, we analyzed 72 families including 174 patients (81 polycythemia vera [PV], 68 essential thrombocythemia [ET], 11 myelofibrosis with myeloid metaplasia [MMM], 12 chronic myeloid leukemia), 1 systemic mastocytosis, and 1 chronic myelomonocytic leukemia (CMML).
|
16537803 |
2006 |
Leukemia, Myelomonocytic, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, one of the patients with SM and the patient with CNL with JAK2 V617F had a history of lymphoma, and this patient with SM also had associated myelofibrosis and CMML.
|
15860661 |
2005 |